Lundbeck scores FDA approval, reorganizes

Share this article:
Lundbeck and Takeda's Brintellix
Lundbeck and Takeda's Brintellix

The FDA passed Lundbeck and Takeda an under-the-wire approval, green-lighting the company's depression drug Brintellix just before the government went into shutdown mode at midnight.

The two companies are already set to promote the drug: Bloomberg reported in August that the pair had decided prior to approval to send more than 200 sales reps into the field to promote the drug, which Jefferies analyst Peter Welford called “a substantial blockbuster” in a Tuesday research note.

Welford wrote that the drug's potential is increased by what it does not do: cause weight gain. Welford projected $1.3 billion in worldwide sales, and noted that pre-approval discussions with clinicians showed that they liked its tolerability profile and titration flexibility – the drug will be available in 5mg, 10mg and 20mg doses.

Brintellix will not be an immediate financial fix, however. Welford forecasted Lundbeck's sales to slide in 2015 and 2016, as generics eat into sales of Cipralex, Azilect, Sabril and Xenazine, providing context for Monday's announcement that Lundbeck was implementing a re-org that will “impact” 180-200 jobs.

This is not to be confused with layoffs. A spokesperson for Lundbeck told MM&M via email that these jobs will be jumping locations from Europe to Poland. The positions are in human resources, IT, finance and sourcing and unrelated to the June news that 50-55 jobs were being eliminated.

The reorganization announced Monday includes organizing its 30 European affiliates into 10 business units. Commercial operations are also being remapped, and will be broken out into six regions: Europe, US, Canada, Asia, Latin America and the Middle East & global operations.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...